In Appetite stimulant Cyaptin with Calcium Suspension increases hunger by constantly increasing the energy requirements of an individual. It promotes the desire to eat and therefore, is an effective way of managing undernutrition or malnutrition. Calcium present in Cyaptin with Calcium Suspension makes the bones strong and helps in overall growth and development. You may see an improvement in your appetite after taking Cyaptin with Calcium Suspension in few weeks.
Cyaptin with Calcium Suspension may cause excessive drowsiness with alcohol.
Cyaptin with Calcium Suspension may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
Cyaptin with Calcium Suspension is probably safe to use during breastfeeding. Limited human data suggests that the drug does not represent any significant risk to the baby. Unless Cyaptin with Calcium Suspension is used to lower the prolactin levels in the mother, it should be avoided as it might interfere with breastfeeding.
Cyaptin with Calcium Suspension may cause side effects which could affect your ability to drive. Cyaptin with Calcium Suspension may cause dizziness, sedation, and hypotension in elderly patients. This may affect your ability to drive.
Cyaptin with Calcium Suspension should be used with caution in patients with kidney disease. Dose adjustment of Cyaptin with Calcium Suspension may be needed. Please consult your doctor. Use of Cyaptin with Calcium Suspension may not be advised in patients with severe kidney disease.
Cyaptin with Calcium Suspension is probably safe to use in patients with liver disease. Limited data available suggests that dose adjustment of Cyaptin with Calcium Suspension may not be needed in these patients. Please consult your doctor.
FDC Ltd | B-8, MIDC Area, Waluj - 431 136, Dist. Aurangabad, Maharashtra
Marketer/Manufacturer: Abbott || ₹14.5/tablet (25% cheaper)
No customer reviews yet.
FDA approved prescribing information. Levocitrizine; 1995 [revised May 2007]. [Accessed 01 Apr. 2019] (online) Available from: Read More
European Medicne Agency. Revised assessment report: Ambroxol and bromhexine containing medicinal products. 2015. [Accessed 01 Apr. 2019] (online) Available from: Read More
ScienceDirect. Ambroxol. [Accessed 01 Apr. 2019] (online) Available from: Read More
Levocitrizine. Slough, Berkshire: UCB Pharma Limited; 2007 [revised 27 Mar. 2019]. [Accessed 01 Apr. 2019] (online) Available from: Read More
Marketer/Manufacturer: The Pharmed Research Lab Pvt Ltd || ₹14.5/tablet (25% cheaper)